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Abstract
Interleukin 17A (IL-17A) has been associated with protective rather than pathogenic
response in Chagas disease (ChD). However, it is not established whether or not IL-17A-
mediated immune response is correlated with patient’s left ventricular (LV) function in ChD.
To address this question we have gathered cardiac functional parameters from ChD
patients and analysed the possible relationship between their plasma IL-17A levels and LV
function. Plasma IL-17A levels were measured by BD Cytometric Bead Array (CBA) in 240
patients with positive specific serology for Trypanosoma cruzi (T. cruzi) grouped as indeter-
minate (IND) and Chagas cardiomyopathy (CARD) forms. The levels of IL-17A in ChD
patients were compared with 32 healthy individuals, mean age of 39 years, 50% male, that
were also included as a control group (non-infected [NI]). The overall mean age of ChD
patients was 46 years and 52% were male. The IND group included 95 asymptomatic
patients, with ages ranging from 27 to 69 years (mean of 43 years), and 42.1% of them were
male. The CARD group included 145 patients, which 58.6% were male, with ages ranging
from 23 to 67 years (mean of 49). The IND group presented substantially higher levels of IL-
17A, median of 26.16 (3.66–48.33) as compared to both the CARD group, median of 13.89
(3.87–34.54) (P <0.0001), and the NI group, median of 10.78 (6.23–22.26) (P <0.0001). The
data analysis demonstrated that the IND group comprises a significantly greater proportion
(P <0.001) of high IL-17A producers (52.6%, 50 of 95 subjects) than do the other groups. A
significant direct correlation was verified between IL-17A levels and cardiac function
expressed by LV ejection fraction (LVEF), LV diastolic diameter (LVDd), and body surface
area (BSA)-indexed LVDd as well as ratio of the early diastolic transmitral flow velocity to
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early diastolic mitral annular velocity (E/e’) in both groups. We demonstrated that plasma IL-
17A levels has an accurate sensitivity and specificity to predict heart failure in serology-posi-
tive patients and might be a useful parameter to distinguish patients with or without cardiac
impairment. This study indicates a consistent relationship between high expression of IL-
17A and better LV in human chronic ChD. Our data raise the possibility that IL-17A plays an
important immunomodulatory role in the chronic phase of ChD and might be involved in pro-
tection against myocardial damage.
Introduction
The immunopathogenesis of Chagas disease (ChD) is complex and not yet fully understood
[1]. Interleukin 17A (IL-17A) is a proinflammatory cytokine that contributes to host protec-
tion against a range of infectious pathogens by inducing the recruitment of neutrophils and
secretion of inflammatory mediators [2, 3]. Prior literature has suggested an important role for
IL-17A in the resolution of infection with the protozoan parasite T. cruzi [4–6]. Moreover, pre-
liminary data both from experimental [7] and human T. cruzi infection studies [8–10] have
indicate that this cytokine is associated with protective rather than pathogenic responses.
Studies on IL-17A in human ChD are limited and have usually employed small sample size
[8–11]. In addition, only in one study, correlation analysis was performed between this cyto-
kine and parameters of cardiac function such as LVEF and LVDD [10]. Confliting evidence
exists regarding the role of IL-17A-mediated immune response in human ChD. Such investi-
gations require larger sample sets of cases and controls. Given these findings, this study was
designed to evaluate the plasma IL-17A levels in patients with indeterminate and severe car-
diac forms of ChD and to assess whether or not IL-17A-mediated immune response would
correlate with patients’ LV function.
These clinical forms were selected to this study since they represent extremes of the wide
clinical spectrum of ChD. The indeterminate form of ChD is defined by the presence of T.
cruzi infection, absence of symptoms, and of electrocardiographic and radiologic abnormali-
ties [12]. In contrast, Chagas cardiomyopathy is characterized by chronic myocarditis that
involves all cardiac chambers and damage to the conduction system [13]. This most severe
form of ChD manifests as three frequent syndromes that can co-occur in an individual patient:
heart failure, cardiac arrhythmia, and thromboembolism [14]. These patients are of special
interest for studies involving the natural development of the disease and the possible determi-
nants of clinical outcome. The identification of non-invasive markers related to morbidity and
prognosis may allow the recognition of subgroups of patients with potential to progress toward
the severe forms of ChD, which should require special attention and specific therapeutic
approaches in order to prevent or delay the unfavorable outcome of these patients. In this
study, we gathered cardiac functional parameters from ChD patients, aged 23 to 69 years and
analysed the possible relationship between their plasma IL-17A levels and LV function.
Materials and methods
Study population
This study comprises 240 patients in the chronic phase of ChD from endemic areas within the
state of Minas Gerais, Brazil, who were identified and selected at the Referral Outpatient Cen-
ter for Chagas Disease at the Clinical Hospital of the Universidade Federal de Minas Gerais
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(UFMG), Brazil. All patients were tested positive for T. cruzi and fulfilled eligibility criteria.
Positive specific serology for T. cruzi was determined by two or more tests (indirect immuno-
fluorescence, enzyme-linked immunosorbent assay [ELISA], or indirect hemagglutination).
The study protocol was approved by the Research Ethics Committee of the Universidade Fed-
eral de Minas Gerais (protocol COEP-ETHIC 502/11) and Centro de Pesquisas Rene´ Rachou
(protocol CEPSH-CPqRR 15/2011) and all participants provided written informed consent.
Inclusion criteria were the diagnosis of IND defined as asymptomatic individuals, in sinus
rhythm, with no significant alterations in electrocardiography, chest radiograph, and echocar-
diogram, and diagnosis of CARD characterized by the echocardiographic finding of a dilated
left ventricle with impaired ventricular systolic function. LVEF, LVDd, and E/e’ ratio were
used as variables of LV function, where LVEF<55% and LVDd/BSA31mm were used to
define CARD patients [12]. Healthy individuals from a non-endemic area for ChD and show-
ing negative serological tests for the infection were included as a control group, NI. None of
the patients were undergoing etiological treatment nor had been previously treated for T. cruzi
infection. Individuals with any other chronic inflammatory disease, thyroid dysfunction, val-
vular heart disease, rheumatic or ischemic heart disease, coronary artery disease, systemic arte-
rial hypertension, chronic obstructive pulmonary disease, hydroelectrolytic disorders, kidney
disease, diabetes mellitus, alcoholism, pregnancy defined by laboratorial criteria, and other
cardiomyopathies or infectious diseases were excluded from this study. Eligible and consenting
subjects were enrolled on the study.
Ecochardiogram evaluation
A standard transthoracic two-dimensional (2D) echocardiogram was performe using commer-
cially available equipment (iE33, Philips Medical Systems, Andover, MA) according to recommen-
dations of the American Society of Echocardiography [15]. LV ejection fraction was calculated
according to the modified Simpson’s rule.LV diastolic function was assessed by pulsed Doppler of
the mitral inflow and by tissue Doppler imaging measurements, obtained at the medial and lateral
border of the mitral annulus in the apical 4-chamber view [15]. Systolic tissue Doppler velocity
(S´), and early (e´) and late (A´) diastolic tissue velocities were acquired, and the ratio of the mitral
E velocity to the mean e´’ was calculated (E/e´).
Multiplexed bead-based immunoassay
A BD CBA Human Th1/Th2/Th17 cytokine Kit (Catalog No. 560484; Becton Dickinson Bio-
sciences, San Jose, CA, USA) was used to quantify IL-17A concentration in plasma, following
manufacturer instructions. The data were acquired in a BD FACSCalibur flow cytometry sys-
tem (BD Biosciences, San Jose, CA, USA) and analyses performed using BD FCAP Array v3.0
software (BD Biosciences, San Jose, CA, USA). The standard curve was determined using a
five-parameter logistic (5-PL) equation. The results were based on standard concentration
curve and expressed as picogram per milliliter (pg/mL).
Statistical analysis
Statistical comparative analyses were performed in groups of two between the NI, IND, and
CARD groups, using the non-parametric Kruskal-Wallis test and Mann-Whitney U test,
together with the Bonferroni correction (significance level, 0.05/3 = 0.0167) [16]. Categorical
data were presented as numbers and percentages, and continuous data were expressed as
mean ± standard deviation (SD) or median and interquartile range (25%-75%), as appropriate,
based on the prior Shapiro-Wilk normality test.
Interleukin 17 in human Chagas disease
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IBM SPSS Statistics 20.0 software (SPSS Inc., Chicago, Illinois) was used for all analyses.
Graphs were prepared using GraphPad Prism v7.0 software (San Diego, CA, USA). Results
were nominally significant at two-sided P< 0.05.
Results
Characteristics of the study population
The major clinical, eletrocardiographic, and echocardiographic characteristics of the study
population are reported in Table 1. A total of 272 subjects were included in the study. Overall,
this cohort consists of middle-aged (mean age, 46 years) subjects with 52% of males. The mean
age of ChD patients was 46±9.9 years, and 52% were male. The IND group included 95 asymp-
tomatic patients, with ages ranging from 27 to 69 years (mean of 43±9). The CARD group
included 145 patients, with ages ranging from 23 to 67 years (mean of 49±10). The CARD
group had significantly greater proportion of males than other groups and most of the CARD
patients were in NYHA functional class I or II (84.1%). Moreover, 32 healthy individuals, 50%
males, ranging from 27 to 58 years of age (mean of 39±10), were also included as the NI group.
As expected, the mean QRS duration in the IND group was similar to that observed in the NI
group, 83.2±2.6 ms and 81.4±2.9 ms, respectively. QRS duration was increased in all CARD
patients with mean of 124.6±26 ms. Corrected QT duration was within normal limits and was
similar in the three groups (Table 1). Right bundle-branch block (RBBB) was the most fre-
quent electrocardiogram (ECG) abnormality, observed in 52 of 145 (36%) of CARD patients.
Of the CARD patients with RBBB, 41 patients had associated left anterior fascicular block
(LAFB) and 1 had left posterior fascicular block (LPFB). Left bundle branch block (LBBB) and
first-degree atrioventricular blocks (AVB) were detected, respectively, in 3 (2%) and 13 (9%) of
145 CARD patients. Atrial fibrillation was present in 6 of 145 (4%) of CARD patients and all
these patients were taking anticoagulants. Neither NI subjects nor IND patients had RBBB
Table 1. Clinical, eletrocardiographic, and echocardiographic characteristics of the study population.
Characteristic Healthy control (n = 32) Indeterminate form (n = 95) Chagas cardiomyopathy (n = 145) P-value*
Age, yr 39±10 43±9 49±10 0.0012
Male sex, n (%) 16 (50) 40 (42.1) 85 (58.6) 0.0026
Body-surface area, m2 1.8 (1.7, 1.9) 1.8 (1.7, 1.8) 1.6 (1.6, 1.7) 0.0189
Heart rate, beats/min 69 (63, 76) 68 (62, 76) 63 (60, 74) 0.0203
Blood pressure, mm Hg
• Systolic 116±8 119±10 107±12 <0.0001
• Diastolic 79±7 82±7 71±10 <0.0001
Eletrocardiographic
• QRS duration, ms 81.4±2.9 83.2±2.6 124.6±26 0.0037
• Corrected QT interval, ms 451±32 453±35 453±41 0.4565
Echocardiographic
• LV ejection fraction, % 68 (66, 70) 66 (63, 69) 38 (29, 47) <0.0001
• LV end-diastolic diameter, mm 45 (43, 47) 48 (45, 50) 63 (59, 68) <0.0001
• LV end-diastolic diameter/BSA, mm/m2 25 (23, 26) 27 (25, 28) 37 (34, 41) <0.0001
• E/e’ ratio 7.3 (6.2, 10.1) 8.2 (6.3, 10.1) 10.3 (7.5, 14.2) <0.0001
Values are expressed as mean and standard deviation (mean±SD), median (interquartile range), or absolute number and percentage. E/e’ratio, ratio of the
early diastolic transmitral flow velocity to early diastolic mitral annular velocity; LAFB, left anterior fascicular block; LV, left ventricular; RBBB, right bundle
branch block; RBBB, left bundle branch block.
*P-value< 0.05 (two-sided) for comparison between the groups (Kruskal-Wallis test).
doi:10.1371/journal.pone.0172833.t001
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(with or without associated LAFB), LBBB, LPFB, or other significant ECG abnormality that
would motivate the exclusion from this study.
Plasma IL-17A levels are associated with morbidity in Chagas disease
To determine whether the levels of IL-17A are associated with morbidity in ChD, the concentra-
tion of this cytokine was evaluated in the plasma from IND and CARD patients as well as healthy
individuals. Differences among the three groups were observed for IL-17A (P<0.0001). The
IND group presented substantially higher levels of IL-17A, median of 26.16 (3.66–48.33) as com-
pared to the CARD group, median of 13.89 (3.87–34.54) (P<0.0001), and the NI group, median
of 10.78 (6.23–22.26) (P<0.0001) (Fig 1). To establish the IL-17A cutoff that would permit the
identification of patients with IND and CARD forms of ChD, an analysis was performed that
allows a division of the individuals into three categories: low (3.66–12.69 pg/mL), intermediate
(12.88–24.88 pg/mL), and high (24.89–48.33 pg/mL) IL-17A producers. To that end, these three
groups were identified based on the detailed analysis of individual levels of IL-17A obtained for
NI, IND, and CARD groups; a statistical method based in tertiles [17] was employed to deter-
mine the cut-off for IL-17A plasma levels, as shown in Fig 1. Data analysis demonstrated that the
IND group comprises a significantly higher frequency of intermediate (40% 38/95) and high
(52.63% 50/95) IL-17A producers than do the other groups (P<0.001) (Fig 1). In contrast, most
of the CARD patients displayed values of IL-17A levels that are below the cutoff for low IL-17A
producers, being significantly lower than IND patients (7.36%, 7/95) (P<0.001), while approxi-
mately 30.34% (44/145) and 26.89% (39/145) of CARD patients were identified as intermediate
and high IL-17A producers, respectively (Fig 1). None of the individuals were identified as high
IL-17A producers in the NI group (Fig 1).
High IL-17A levels correlated with better left ventricular function in
Chagas disease
In order to investigate the existence of association between IL-17A levels and LV function in
ChD, correlation analysis was performed between the plasma levels of IL-17A in either ChD
patients and healthy non-chagasic individuals and variables of LV systolic and diastolic ven-
tricular functions. Data analysis indicated a relationship between lower levels of IL-17A and
worse cardiac function in ChD. Interestingly, a significant direct correlation was identified
between IL-17A levels and LVEF in ChD patients as a whole (Fig 2A). In addition, a significant
inverse correlations between IL-17A levels and either LVDd (Fig 2B), LVDd/BSA (Fig 2C) or
E/e’ ratio (Fig 2D) could be observed. In contrast, no linear relationship could be found
between IL-17A levels and variables of LV ventricular function in the NI group.
When the association between the levels of IL-17A and LVEF was investigated in the IND
group, a significant direct correlation was observed (r = 0.6972, P<0.0001) (Fig 3A). In con-
trast, a significant inverse correlation could be found between IL-17A levels and both LVDd
(r = -0.3974, P<0.0001) (Fig 3B) and LVDd/BSA (r = -0.3427, P<0.0001) in the same group
(Fig 3C). Plasma IL-17A levels were also inversely correlated with E/e’ ratio in the IND group
(r = -0.3694, P<0.0001) (Fig 3D). A significant direct correlation was identified when IL-17A
levels were compared with LVEF in the CARD group (r = 0.5309, P<0.0001) (Fig 3E). Con-
versely, inverse correlation was observed between IL-17A levels and both LVDd (r = -0.3029,
P = 0.0006) (Fig 3F) and LVDd/BSA (r = -0.4017, P = 0.0001) (Fig 3G) in the CARD group.
Similar results could be found when comparing IL-17A levels and E/e’ ratio in the same group
(r = -0.3371, P = 0.0001) (Fig 3H).
Although, the IL-17A levels correlated directly with better left ventricular function in
chronic ChD, we sought to obtain additional evidence of the strength of association.
Interleukin 17 in human Chagas disease
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Considering that in clinical workup the determination of plasma IL-17A levels would be
achieved to downstream to Chagas serology, a Receiver Operating Characteristic (ROC) curve
analysis was performed based on the IND and CARD groups. The contribution of IL-17A lev-
els to discriminate diseased cases with heart failure (CARD) from infected patients without
cardiac impairment (IND) is shown in the ROC curve (Fig 4). The area under the ROC curve
(AUC) to predict HF (Fig 4) was 0.78 (95% CI: 0.722, 0.838; P<0.0001). The optimal threshold
of IL-17A to predict CARD in serology-positive patients was less than 17.97 pg/mL based on
accurate sensitivity and specificity of 61% and 84%, respectively.
Discussion
The principal findings of this study were: (a) The plasma IL-17A levels were at least 2-fold
higher in the IND group than those in the NI and CARD groups; (b) The IND group presented
a significantly greater proportion of high IL-17A producers than do the other groups; and (c)
high plasma levels of IL-17A is associated with better LV function in ChD.
There was also a greater proportion of males in the CARD group; however, an association
between male sex and risk progression to chronic Chagas cardiomyopathy (CCC) or death in
patients with ChD has previously been reported [18–20]. A previous study in a endemic area
including asymptomatic T. cruzi–seropositive blood donors demonstrated that male sex was
Fig 1. Analyses of plasma IL-17A levels in the study groups. Representative scatter plot graph of plasma
IL-17A used to establish the cutoff to define low, intermediate, and high cytokine producers. Low IL-17A
producers were defined by values of lower than the first tertile. Intermediate IL-17A producers were defined by
values equal to or lower than the second tertile, while high IL-17A producers were defined by values higher
than or equal to the second tertile [18]. The results were expressed by pg/mL. Results were considered
significant with a P-value <0.05.
doi:10.1371/journal.pone.0172833.g001
Interleukin 17 in human Chagas disease
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associated with the onset of cardiomyopathy [21]. Therefore, in the present study the greater
proportion of male in CARD group was expected.
The present study included quantitative cardiac functional parameters to assess the LV
function of the study population. In CCC patients, impairment of LV filling and systolic dys-
function usually coexist [22–24] and are consistent predictors of functional capacity [25, 26]
and mortality [27] in this severe form of ChD. A previous study showed that patients with
mild or moderate systolic dysfunction, the E/e’ ratio (an important marker of LV filling pres-
sure) of more than 15 was powerful in predicting prognosis in patients with Chagas cardiomy-
opathy [28].
Higher levels of IL-17A in the IND group compared to the NI group might be explained by
a possible effect of T. cruzi infection inducing immune response even in these asymptomatic
patients. This result is in agreement with findings from previous studies [8–10]. A significant
Fig 2. Correlation analysis between plasma IL-17A levels and echocardiographic parameters of left ventricular function in Chagas
disease patients. Correlation analysis was performed between plasma IL-17A levels and variables of LV function (LVEF, LVDd, LVDd/BSA,
and E/e’ ratio) in the ChD patients as a whole. The analysis was performed using the Spearman correlation coefficient, and results were
considered significant when P-value <0.05. Significant differences are indicated in each graph together with the r value.
doi:10.1371/journal.pone.0172833.g002
Interleukin 17 in human Chagas disease
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Fig 3. Correlation analysis between plasma IL-17A levels and echocardiographic parameters of left
ventricular function according to the form of Chagas disease. Correlation analysis was performed
between plasma IL-17A levels and parameters of LV function (LVEF, LVDd, LVDd/BSA, and E/e’ ratio) in the
IND (n = 95, A, B, C, and D, respectively) and CARD (n = 145, E, F, G, and H, respectively) groups. The
analysis was performed using the Spearman correlation coefficient, and results were considered significant
when P-value <0.05. Significant differences are indicated in each graph together with the r value.
doi:10.1371/journal.pone.0172833.g003
Interleukin 17 in human Chagas disease
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frequency of IND patients presented high levels of IL-17A, whereas most of the CARD
patients expressed low levels of this cytokine. Although, low and high producers of IL-17A
were observed in both groups. The importance of this differential expression throughout
the chronic phase of ChD and to the disease outcome remains unknown. A possible expla-
nation, for the broad distribution range of IL-17A levels produced by CARD patients, could
be the difference in the expression of immune response determined by different host’s gene-
tic patterns. Furthermore, it could be hypothesized that lower IL-17A producers in the
CARD group would develop an earlier or worse LV function. On the other hand, higher
IL-17A producers in the same group probably would display later and less intense cardiac
morbidity. In contrast, lower IL-17A producers in the IND group would be those likely to
develop myocardial damage, whereas those that show higher levels of this cytokine would
tend to present a later cardiac involvement or remain asymptomatic. In this context, it is
seems reasonable to consider that intermediate IL-17A producers might present an expres-
sion profile resulting of balanced immune response controlled by regulatory mechanisms
such as Foxp3+CD25(high)CD4+ regulatory T cells previously demonstrated by our group
[8]. Nevertheless, the disease progression and clinical future of those patients has not been
established yet and probably involve multiple factors.
Fig 4. Receiver operating characteristics curve of sensitivity of heart failure prediction against
specificity. A risk score was calculated on the basis of the plasma IL-17A levels in the IND and CARD groups
by logistic regression, and the proportion of all cases that score greater than any given cutoff (sensitivity)
against the proportion of the IND patients that would also exceed the same cutoff (specificity) was plotted. The
slope of the tangent line at a cutpoint indicates the likelihood ratio for that value of the test and the diagonal
line represents random prediction.
doi:10.1371/journal.pone.0172833.g004
Interleukin 17 in human Chagas disease
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We also addressed the question of whether or not IL-17A-mediated immune response is
correlated with patients’ LV. Notably, a significant correlation was observed between the
plasma IL-17A levels in either IND or CARD groups and cardiac involvement expressed by
variables of systolic (LVEF) and diastolic (LVDd, LVDd/BSA and E/e’ ratio) ventricular func-
tion. Overall, these data showed that high plasma levels of IL-17A are associated with better
LV function. Thus, it is tempting to speculate that IL-17A might be linked to a protective role
in the chronic phase of ChD. While our data indicate a consistent relationship between high
IL-17A levels and better cardiac function in human ChD, this and other previous studies in
patients with ChD were cross-sectional and could not establish causality between heart damage
protection and IL-17A expression. In-depth basic and translational investigations aimed at
understanding the molecular immunology and the pathophysiology are needed to elucidate
the mechanisms underlying the IL-17A expression in long-term chronic ChD. Our longitudi-
nal study cohort in progress provide an opportunity to investigate the influence of IL-17A
expression on disease progression and clinical outcome since multiple samples are available
from the same patients and healthy control subjects without ChD.
The findings from prior studies have suggested a possible protective role of IL-17A in
experimental infection models [4] and in human ChD [10]. In order to better understand the
role of IL-17A in T. cruzi infection, IL-17A−/− mice and anti-IL-17A treatment were used as
strategy [4, 5]. In this study, it was verified earlier mortality of IL-17A−/− mice when compared
to mice controls treated with anti-IL-17A. These studies suggest that IL-17A would be relevant
for the balance of immune response and important for parasite control during the chronic
phase of the disease [1]. However, a recent study investigating the role of IL-17A in non-chaga-
sic inflammatory dilalated cardiomyopathy–an important cause of noncongenital heart failure
in individuals under the age of 40, has reported that IL-17A/IL-17RA signaling pathway is
required for the development of the disease [29]. It was demonstrated that IL-17RA−/− develop
limited cardiac enlargement and fibrosis. They further showed that IL-17A was associated
with induction of chemokine production by fibroblasts, which attracts effector cells to the
myocardium and increases inflammation [29]. In ChD context, increased expression of IL-
17A mRNA was found in the myocardial inflammatory infiltrate of CCC patients [30]. In this
cross-sectional study, the expression of IL-17A was evaluated in myocardial samples from 14
end-stage heart failure CCC patients, 8 end-stage heart failure patients with noninflammatory
cardiomyopathies (5 patients with idiopathic dilated cardiomyopathy and 3 patients with
ischemic cardiomyopathy, all seronegative for T. cruzi), and 6 nonfailing donor hearts. How-
ever, patients with indeterminate form of ChD–important subjects to study the immune
response and its association with disease morbidity and mortality in chronic ChD were not
included in the investigation.
In the present study we have examined the expression of IL-17A in plasma samples from a
large set of IND and CARD patients, and healthy controls. We demonstrated that plasma IL-
17A levels has an accurate sensitivity and specificity to predict heart failure in serology-positive
patients and might be a useful parameter to distinguish patients with or without cardiac
impairment, as CARD and IND patients, respectively. Our findings indicate a consistent rela-
tionship between high expression of IL-17A and better LV in human chronic ChD. Nonethe-
less, observations on human plasma samples may not reflect which would be observed in
myocardial LV free wall heart specimens from IND and CARD patients.
IL-17A has been described as a cytokine secreted by T helper 17 cells (Th17). Moreover,
other cells were recognized as IL-17A sources, such as monocytes, neutrophils, and natural
killer T (NKT) cells [2, 3, 31]. Bermejo et al. showed that B cells are the principal source of IL-
17A after infection with the extracellular parasite T. cruzi and that the B cells produce IL-17A
independently of RORγT, which is considered the main transcription factor involved with
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Th17 differentiation [6]. Fibroblasts, macrophages, neutrophils, B and T lymphocytes are con-
sidered target cells of this cytokine [3]. Once IL-17A binds to its receptor, it induces the secre-
tion of inflammatory cytokines (TNF, IL-1 and IL-6) and chemokines (CXCL1, CXCL5, IL-8,
CCL2, and CCL7). Like many cytokines, lL-17A may play a role in tumor development,
encephalomyelitis, arthritis, systemic lupus erythematosus, inflammatory bowel disease, sepsis,
and allergic diseases [31, 32]. In contrast to pathogenic roles of IL-17A in autoimmune and
chronic inflammatory diseases, this cytokine promotes host defense against pathogens at epi-
thelial and mucosal tissues which include the skin, lung, and instetine [2, 3, 31].
IL-17A induces the expression of several proinflammatory chemokines and cytokines
through activation of NF-κB, MAPKs and C/EBPs cascades [32–34]. Furthermore, other stud-
ies have indicated that IL-17A can activate JAK–PI3K and JAK–STAT pathways [35, 36].
However, how IL-17A contributes to the activation of these pathways is unclear. Hence, fur-
ther investigations will be necessary to identify the signaling pathway and the effects of IL-17A
in distinct cell populations such as CD8+ T cells, macrophages, and NKT cells. It is also impor-
tant to evaluate the signaling induced by IL-17A considering the presence of antigens and dif-
ferent gene polymorphisms.
In this study, we included a large and homogenous cohort of ChD patients who have not
been previously treated for T. cruzi infection and performed a strategic analysis to establish an
appropriate determination of cutoff edge that allows the division of IL-17A levels in three cate-
gories [37]. This method of analysis dichotomize low and high producers of IL-17A –extremes
of expression, and express better a biological phenomenon that presents a wide dispersion.
In conclusion, our data raise the possibility that IL-17A plays an important immunomodu-
latory role in the chronic phase of ChD and might be involved in protection against myocar-
dial damage. However, there are still many open questions pertaining the role of IL-17A in T.
cruzi infection [38] and further studies will be necessary to address them. To elucidate the role
of IL-17A in the development or control of chronic Chagas cardiomyopathy, we are now also
investigating whether lower levels of IL-17A are related to higher morbidity, expressed by
arrhythmogenic substrates, in CARD patients and either by the presence of subclinical alter-
ations or arrhythmogenicity in IND patients. Understanding the role of this cytokine may pro-
vide useful information for better comprehension of the pathogenesis of ChD and contribute
to the proper management and treatment of the patients.
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